Hepatocellular Carcinoma
Conditions
Brief summary
The current understanding of PR104 justifies the evaluation of PR104 with sorafenib in patients with hepatocellular carcinoma. These include: * Hypoxia. Hepatocellular Carcinoma (HCC) is likely to demonstrate a level of hypoxia sufficient to activate PR104 to its active metabolites PR104H and PR104M. In addition, in preclinical models, sorafenib has been demonstrated to increase the degree of hypoxia in tumors following treatment. * Non-overlapping toxicity. PR104 and sorafenib do not share major toxicities. It is anticipated that both drugs can be administered at their full single agent dose when used in combination. * Aldo-keto reductase 1C3 (AKR1C3). HCC has been shown to express high levels of AKR1C3 which should lead to selective activation of PR104 within both hypoxic and oxic HCC cells. * Preclinical data. The use of sorafenib and PR104 alone and in combination in a hepatocellular carcinoma model demonstrates activity of PR104 as a single agent and increased activity when PR104 and sorafenib are used in combination. The current study will provide an estimate of the activity of PR104 in subjects with HCC. This information will prove valuable in defining the future clinical development of PR104, and in determining if PR104 has sufficient activity in HCC to warrant a larger phase III registration study in this indication. Primary objectives * Phase I: Determine the maximum tolerated dose (MTD) of PR104 when used in combination with standard dose sorafenib * Phase II: Estimate the response rate (RR) of PR104/sorafenib \[Note: Phase II was never initiated\] Secondary objectives * Evaluate survival * Evaluate Progression Free Survival (PFS) * Evaluate time to progression (TTP) * Evaluate safety * Evaluate the pharmacokinetics (PK) of sorafenib, PR104 and PR104 metabolites * Collect diagnostic biopsy samples for the determination of aldo-keto reductase 1C3 * Collect plasma samples for assessment of potential biomarkers of tumor hypoxia
Detailed description
A randomized phase I/II, multi-center, open-label, study with a single arm phase I portion to determine the appropriate dose of PR104 combined with sorafenib, followed by a phase II portion with randomization between sorafenib and sorafenib/PR104. Following informed consent, subjects will undergo baseline evaluation with history, physical exams, blood work and disease assessment. Selected subjects will undergo PK assessment of sorafenib, PR104 and PR104 metabolites. In the phase I portion of the study, the starting dose of PR104 will be 770 mg/mg2 in combination with standard dose sorafenib. PR104 will be administered on an every 4 week schedule with the dose of PR104 escalated in a standard phase I fashion (3 subjects per cohort, dose escalation between cohorts) in order to determine the MTD of PR104. Cohorts may be expanded up to 12 subjects to better define toxicity at a particular dose level. Following determination of the MTD of PR104, new subjects will be entered into the phase II portion of the study. \[Note: the Phase II portion was never initiated\] In the phase II portion of the study, subjects will be randomized between sorafenib, 400 mg, by mouth (PO), twice a day (the approved dose and schedule) versus sorafenib with PR104 at the dose determined in the phase I portion of the study. PR104 will be administered every 4 weeks (one cycle). Subjects will be evaluated each week during cycle 1 and every two weeks thereafter. A disease assessment will be performed after every two cycles. Subjects with progression will be removed from study. Subjects with a response or stable disease may continue on study if this is considered beneficial by their physician.
Interventions
DRUGPR104 550 mg/m^2 + sorafenib
550 mg/m\^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
DRUGPR104 770 mg/m^2 + sorafenib
770 mg/m\^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
Sponsors
Proacta, Incorporated
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Advanced-stage hepatocellular carcinoma considered non-operable that is suitable for treatment with sorafenib. Subjects who have demonstrated progression following initial surgical or locoregional therapy are eligible * Confirmed hepatocellular carcinoma by pathological analysis (tissue aspirate or biopsy) * No previous systemic therapy for hepatocellular carcinoma * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Child-Pugh liver function class A * Life expectancy of 12 weeks or more * Adequate hematologic function \[Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L; platelet count ≥100×10\^9 per liter; hemoglobin ≥8.5 g per deciliter maintained in the absence of red blood cell transfusions; and prothrombin time international normalized ratio ≤1.7; or prothrombin time ≤2 seconds above control\] * Adequate hepatic function (albumin ≥2.8 g per deciliter; total bilirubin ≤2 mg per deciliter \[51.3 μmol per liter\]; and alanine aminotransferase and aspartate aminotransferase ≤5 times the upper limit of the normal range) * Adequate renal function (serum creatinine ≤1.5 times the upper limit of the normal range or creatinine clearance ≥60 mL/min). * At least one untreated target lesion that could be measured in one dimension, according to the Response Evaluation Criteria in Solid Tumors (RECIST) * Concomitant systemic antiviral therapy allowed
Exclusion criteria
* Previous molecularly targeted therapies or any other systemic treatment for hepatocellular carcinoma * Active concomitant malignancy likely to effect any of the primary or secondary outcome measures in the current study * Women who are pregnant, breast-feeding or planning to become pregnant during the study * Men or women of reproductive-potential who are unwilling to use an effective method of contraception during the study and for 30 days following the last dose of study medication * Evidence of a significant medical disorder or laboratory finding that, in the opinion of the Investigator, compromises the subject's safety during study participation such as: uncontrolled infection or infection requiring a concomitant parenteral antibiotic; uncontrolled diabetes; congestive heart failure; myocardial infarction within 6 months of study; chronic renal disease; or coagulopathy (excluding prophylactic anticoagulation) * Active central nervous system metastatic disease requiring intervention * Less than four weeks since major surgery * Known Human Immunodeficiency Virus (HIV) positivity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum Tolerated Dose (MTD) of PR104 When Used in Combination With Standard Dose Sorafenib in the Phase I Population | 4 weeks (1 cycle) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Tolerability: Serious Adverse Events | 30 days following the last administration of study treatment | The number of participants with at least one Serious Adverse Event was measured. |
| Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Day 1 of Cycles 1 and 2 | — |
| Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Day 1 of Cycles 1 and 2 | — |
| Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Day 1 of Cycles 1 and 2 | — |
| Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Day 1 of Cycles 1 and 2 | — |
| Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Day 1 of Cycles 1 and 2 | — |
| Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Day 1 of Cycles 1 and 2 | — |
Countries
Hong Kong, Singapore, Taiwan, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| PR104 550 mg/m^2 + Sorafenib 550 mg/m\^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily) | 8 |
| PR104 770 mg/m^2 + Sorafenib 770 mg/m\^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily) | 6 |
| Total | 14 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Sponsor decision to terminate the study | 5 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 1 |
Baseline characteristics
| Characteristic | PR104 550 mg/m^2 + Sorafenib | PR104 770 mg/m^2 + Sorafenib | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 1 Participants | 2 Participants |
| Age, Categorical Between 18 and 65 years | 7 Participants | 5 Participants | 12 Participants |
| Age Continuous | 57 years STANDARD_DEVIATION 13 | 59 years STANDARD_DEVIATION 13 | 58 years STANDARD_DEVIATION 13 |
| Region of Enrollment Hong Kong | 1 participants | 3 participants | 4 participants |
| Region of Enrollment Taiwan | 5 participants | 2 participants | 7 participants |
| Region of Enrollment United States | 2 participants | 1 participants | 3 participants |
| Sex: Female, Male Female | 3 Participants | 0 Participants | 3 Participants |
| Sex: Female, Male Male | 5 Participants | 6 Participants | 11 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 8 / 8 | 6 / 6 |
| serious Total, serious adverse events | 5 / 8 | 2 / 6 |
Outcome results
Primary
Maximum Tolerated Dose (MTD) of PR104 When Used in Combination With Standard Dose Sorafenib in the Phase I Population
Time frame: 4 weeks (1 cycle)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohorts 1 and 2 | Maximum Tolerated Dose (MTD) of PR104 When Used in Combination With Standard Dose Sorafenib in the Phase I Population | NA mg/m2 |
Secondary
Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)
Time frame: Day 1 of Cycles 1 and 2
Population: Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cohorts 1 and 2 | Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | AUC Cycle 1 | 5.1 ng.h/ml | Standard Deviation 3.2 |
| Cohorts 1 and 2 | Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | AUC Cycle 2 | 4.3 ng.h/ml | Standard Deviation 2.9 |
| Cohort 2 | Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | AUC Cycle 1 | 11.0 ng.h/ml | Standard Deviation 4.4 |
| Cohort 2 | Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | AUC Cycle 2 | 10.6 ng.h/ml | Standard Deviation 0.1 |
| PR104G | Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | AUC Cycle 1 | 12.3 ng.h/ml | Standard Deviation 1.3 |
| PR104G | Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | AUC Cycle 2 | 15.8 ng.h/ml | Standard Deviation 2.9 |
| PR104S1 | Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | AUC Cycle 1 | 0.26 ng.h/ml | Standard Deviation 0.23 |
| PR104S1 | Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | AUC Cycle 2 | 0.28 ng.h/ml | Standard Deviation 0.1 |
| PR104H | Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | AUC Cycle 1 | 0.47 ng.h/ml | Standard Deviation 0.27 |
| PR104H | Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | AUC Cycle 2 | 0.42 ng.h/ml | Standard Deviation 0.04 |
| PR104M | Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | AUC Cycle 1 | 0.22 ng.h/ml | Standard Deviation 0.09 |
| PR104M | Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | AUC Cycle 2 | 0.19 ng.h/ml | Standard Deviation 0.17 |
Secondary
Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)
Time frame: Day 1 of Cycles 1 and 2
Population: Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cohorts 1 and 2 | Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | AUC Cycle 1 | 2.4 ng.h/ml | Standard Deviation 0.8 |
| Cohorts 1 and 2 | Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | AUC Cycle 2 | 3.3 ng.h/ml | Standard Deviation 0.6 |
| Cohort 2 | Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | AUC Cycle 1 | 19.7 ng.h/ml | Standard Deviation 9.7 |
| Cohort 2 | Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | AUC Cycle 2 | 22.7 ng.h/ml | Standard Deviation 18.2 |
| PR104G | Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | AUC Cycle 1 | 6.4 ng.h/ml | — |
| PR104G | Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | AUC Cycle 2 | 7.6 ng.h/ml | — |
| PR104S1 | Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | AUC Cycle 2 | 0.31 ng.h/ml | Standard Deviation 0.21 |
| PR104S1 | Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | AUC Cycle 1 | 0.30 ng.h/ml | Standard Deviation 0.23 |
| PR104H | Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | AUC Cycle 1 | 0.81 ng.h/ml | Standard Deviation 0.71 |
| PR104H | Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | AUC Cycle 2 | 1.07 ng.h/ml | Standard Deviation 1.02 |
| PR104M | Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | AUC Cycle 1 | 0.18 ng.h/ml | Standard Deviation 0.13 |
| PR104M | Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | AUC Cycle 2 | 0.25 ng.h/ml | Standard Deviation 0.18 |
Secondary
Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)
Time frame: Day 1 of Cycles 1 and 2
Population: Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cohorts 1 and 2 | Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Cmax Cycle 1 | 3.2 ng/ml | Standard Deviation 1.1 |
| Cohorts 1 and 2 | Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Cmax Cycle 2 | 4.3 ng/ml | Standard Deviation 0.7 |
| Cohort 2 | Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Cmax Cycle 1 | 15.8 ng/ml | Standard Deviation 8.9 |
| Cohort 2 | Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Cmax Cycle 2 | 14.6 ng/ml | Standard Deviation 10.4 |
| PR104G | Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Cmax Cycle 1 | 4.9 ng/ml | — |
| PR104G | Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Cmax Cycle 2 | 5.8 ng/ml | — |
| PR104S1 | Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Cmax Cycle 1 | 0.21 ng/ml | Standard Deviation 0.18 |
| PR104S1 | Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Cmax Cycle 2 | 0.17 ng/ml | Standard Deviation 0.17 |
| PR104H | Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Cmax Cycle 1 | 0.72 ng/ml | Standard Deviation 0.8 |
| PR104H | Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Cmax Cycle 2 | 0.69 ng/ml | Standard Deviation 0.78 |
| PR104M | Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Cmax Cycle 1 | 0.12 ng/ml | Standard Deviation 0.12 |
| PR104M | Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | Cmax Cycle 2 | 0.16 ng/ml | Standard Deviation 0.13 |
Secondary
Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)
Time frame: Day 1 of Cycles 1 and 2
Population: Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cohorts 1 and 2 | Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | T1/2 Cycle 1 | 0.15 hr | Standard Deviation 0.1 |
| Cohorts 1 and 2 | Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | T1/2 Cycle 2 | 0.17 hr | Standard Deviation 0.11 |
| Cohort 2 | Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | T1/2 Cycle 1 | 0.75 hr | Standard Deviation 0.35 |
| Cohort 2 | Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | T1/2 Cycle 2 | 0.85 hr | Standard Deviation 0.2 |
| PR104G | Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | T1/2 Cycle 1 | 0.62 hr | Standard Deviation 0.08 |
| PR104G | Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | T1/2 Cycle 2 | 0.67 hr | Standard Deviation 0.17 |
| PR104S1 | Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | T1/2 Cycle 1 | 0.87 hr | Standard Deviation 0.11 |
| PR104S1 | Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | T1/2 Cycle 2 | 0.79 hr | Standard Deviation 0.14 |
| PR104H | Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | T1/2 Cycle 1 | 1.37 hr | Standard Deviation 0.18 |
| PR104H | Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | T1/2 Cycle 2 | 1.05 hr | Standard Deviation 0.35 |
| PR104M | Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | T1/2 Cycle 1 | 3.57 hr | Standard Deviation 0.82 |
| PR104M | Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | T1/2 Cycle 2 | 02.93 hr | Standard Deviation 2.48 |
Secondary
Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)
Time frame: Day 1 of Cycles 1 and 2
Population: Participation in pharmacokinetic (PK) sampling was optional to subjects, therefore not all subjects in the study were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cohorts 1 and 2 | Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Cmax Cycle 1 | 7.1 ng/ml | Standard Deviation 3.2 |
| Cohorts 1 and 2 | Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Cmax Cycle 2 | 6.0 ng/ml | Standard Deviation 3.3 |
| Cohort 2 | Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Cmax Cycle 1 | 7.6 ng/ml | Standard Deviation 1.9 |
| Cohort 2 | Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Cmax Cycle 2 | 7.6 ng/ml | Standard Deviation 1 |
| PR104G | Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Cmax Cycle 1 | 9.6 ng/ml | Standard Deviation 2.3 |
| PR104G | Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Cmax Cycle 2 | 10.4 ng/ml | Standard Deviation 2.2 |
| PR104S1 | Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Cmax Cycle 1 | 0.17 ng/ml | Standard Deviation 0.15 |
| PR104S1 | Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Cmax Cycle 2 | 0.18 ng/ml | Standard Deviation 0.07 |
| PR104H | Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Cmax Cycle 1 | 0.21 ng/ml | Standard Deviation 0.11 |
| PR104H | Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Cmax Cycle 2 | 0.20 ng/ml | Standard Deviation 0.05 |
| PR104M | Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Cmax Cycle 1 | 0.04 ng/ml | Standard Deviation 0.02 |
| PR104M | Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group) | Cmax Cycle 2 | 0.04 ng/ml | Standard Deviation 0.02 |
Secondary
Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)
Time frame: Day 1 of Cycles 1 and 2
Population: Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cohorts 1 and 2 | Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | T1/2 Cycle 1 | 0.10 hr | Standard Deviation 0.01 |
| Cohorts 1 and 2 | Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | T1/2 Cycle 2 | 0.09 hr | Standard Deviation 0.01 |
| Cohort 2 | Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | T1/2 Cycle 2 | 0.79 hr | Standard Deviation 0.23 |
| Cohort 2 | Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | T1/2 Cycle 1 | 0.68 hr | Standard Deviation 0.04 |
| PR104G | Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | T1/2 Cycle 2 | 0.50 hr | — |
| PR104G | Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | T1/2 Cycle 1 | 0.53 hr | — |
| PR104S1 | Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | T1/2 Cycle 1 | 0.69 hr | Standard Deviation 0.2 |
| PR104S1 | Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | T1/2 Cycle 2 | 0.90 hr | Standard Deviation 0.44 |
| PR104H | Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | T1/2 Cycle 1 | 0.84 hr | Standard Deviation 0.34 |
| PR104H | Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | T1/2 Cycle 2 | 0.91 hr | Standard Deviation 0.25 |
| PR104M | Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | T1/2 Cycle 2 | 0.99 hr | Standard Deviation 0.52 |
| PR104M | Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group) | T1/2 Cycle 1 | 1.02 hr | Standard Deviation 0.42 |
Secondary
Safety and Tolerability: Serious Adverse Events
The number of participants with at least one Serious Adverse Event was measured.
Time frame: 30 days following the last administration of study treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohorts 1 and 2 | Safety and Tolerability: Serious Adverse Events | 2 participants |
| Cohort 2 | Safety and Tolerability: Serious Adverse Events | 5 participants |